Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Calcitonin (Miacalcin)32 residuesCSNLSTCVLGKLSQELHKLQTYPRTNTGSGTPEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: Miacalcin, Fortical, sCT
Salmon calcitonin is 40 to 50 times more potent than the human version, and it got FDA approval back in 1975. This 32-amino-acid peptide hormone inhibits osteoclasts, the cells that break down bone. The PROOF study reported a 33% vertebral fracture reduction at five years, though a 2025 Frontiers meta-analysis challenged that finding. Bisphosphonates outperform it on every major bone density metric. Calcitonin still holds a specific niche: acute vertebral fracture pain relief that bisphosphonates simply cannot provide, and rapid calcium lowering in hypercalcemic emergencies within two to six hours.
A 33% reduction in vertebral fractures over five years. That was the PROOF study's headline number for calcitonin-salmon (Chesnut et al. 2000)[1], tested in 1,255 postmenopausal women using the 200 IU/day nasal spray. The full name is calcitonin-salmon, also sold as Miacalcin and Fortical. It is a synthetic version of a 32-amino-acid peptide hormone produced by the thyroid's parafollicular C-cells. The mechanism is direct. Calcitonin binds to receptors on osteoclasts (the cells responsible for bone breakdown), triggers cAMP signaling, and causes the cells to retract from the bone surface. Resorption stops within minutes. In the kidneys, it increases urinary calcium excretion, which explains why serum calcium drops fast in hypercalcemic emergencies. Clinicians use it for three FDA-labeled indications: postmenopausal osteoporosis (more than five years post-menopause), symptomatic Paget disease of bone, and hypercalcemia. The standard injectable dose is 100 IU daily subcutaneous. For hypercalcemia, dosing is weight-based at 4 IU/kg every 12 hours. Pain relief from acute vertebral fractures is the benefit that keeps calcitonin relevant; bisphosphonates don't offer that. Current AACE and BHOF guidelines position calcitonin as last-line therapy for osteoporosis. Bisphosphonates and denosumab produce greater BMD gains and stronger fracture risk reductions. The FDA label carries a malignancy signal (4.1% vs. 2.9% placebo across 21 RCTs), though a 2015 meta-analysis (PMC4715844) found this was not statistically significant after excluding basal cell carcinomas. Brand Miacalcin injection was commercially discontinued by Novartis in 2023; generic calcitonin-salmon from Mylan/Viatris remains available.
Calcitonin-salmon binds to the calcitonin receptor (CTR), a G protein-coupled receptor on the surface of osteoclasts. Receptor activation triggers two parallel signaling cascades. First, adenylate cyclase activity increases intracellular cAMP. Second, phospholipase C raises intracellular calcium concentrations. These signals produce rapid structural changes in osteoclasts. The ruffled border (the resorptive surface pressed against bone) collapses. The cells retract. Secretion of cathepsin K and tartrate-resistant acid phosphatase stops. Bone resorption halts within minutes of injection. In the kidneys, calcitonin acts on distal tubular cells to increase urinary excretion of calcium, sodium, and phosphate. This renal effect is why serum calcium drops within two to six hours in hypercalcemia, making calcitonin a useful bridge therapy while slower agents like zoledronic acid take effect. Pain modulation is the third pathway. Proposed mechanisms include stimulation of beta-endorphin release, inhibition of prostaglandin synthesis in bone tissue, and direct action on serotonergic pathways in the central nervous system. The analgesic effect is real and reproducible; the exact mechanism has not been fully pinned down. One important limitation: salmon calcitonin differs from the human form at 16 of 32 amino acid positions. That gives it stronger receptor binding and slower enzymatic degradation. It also means the immune system may generate neutralizing antibodies over time, causing tolerance.
FDA-approved for postmenopausal osteoporosis, Paget disease of bone, and hypercalcemia. Rapid analgesic effect for acute bone pain is well-supported. PROOF study (2000) showed 33% vertebral fracture reduction with 200 IU/day nasal spray; however, a 2025 Frontiers meta-analysis (pharmacovigilance + RCT) found no significant fracture prevention with calcitonin analogs. Hypercalcemia management (2-6h onset) is robust and guideline-supported. All current guidelines (AACE, BHOF, NICE) position calcitonin as last-line for osteoporosis.
PROOF Study (Chesnut et al. 2000, PMID 10996576): 200 IU/day nasal spray, 33% vertebral fracture reduction at 5 years in postmenopausal osteoporosis. Contested by: Frontiers Pharmacol 2025 meta-analysis (DOI 10.3389/fphar.2025.1514387): no significant non-vertebral or vertebral fracture prevention across calcitonin analog RCTs.
Inferior to bisphosphonates and denosumab on all major efficacy metrics. Malignancy signal in FDA label (4.1% vs 2.9% placebo, 21 RCTs). EMA withdrew nasal spray from osteoporosis indication (Feb 2013). FDA advisory panel voted 12-9 against continued osteoporosis marketing (2013). PROOF study used nasal spray 200 IU/day: injectable 100 IU/day lacks direct fracture-endpoint RCT data. Brand Miacalcin discontinued 2023 (generics available). Tachyphylaxis limits long-term efficacy.
Niche use only. Community primarily reaches for calcitonin when bisphosphonates are contraindicated or cause intolerable side effects, or specifically for bone pain relief from acute vertebral fractures. Very low Reddit injection footprint. Main appeal: analgesic effect that bisphosphonates cannot provide.
Science and community agree calcitonin is not first-line for osteoporosis and is inferior to bisphosphonates for BMD. Both acknowledge analgesic benefit for acute bone pain. Science supports specific FDA-labeled indications (hypercalcemia, Paget); community uses it primarily as a bisphosphonate substitute for pain. No off-label dosing experimentation documented: community usage mirrors the FDA label.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 50 IU | Daily |
| Moderate | 100 IU | Daily |
| Aggressive | 200 IU | Daily |
Calcitonin-salmon injection comes as a pre-filled solution at 200 IU/mL. No reconstitution, no bacteriostatic water, no mixing math. The standard therapeutic dose is 100 IU, which is 0.5 mL from the vial (draw to 50 units on a U-100 insulin syringe). Do the skin test first. This isn't optional. Dilute to 10 IU/mL with normal saline, inject 0.1 mL intracutaneously on the inner forearm, wait 15 minutes. Any wheal or redness means you don't proceed. Evening dosing reduces nausea. Let the vial sit out of the fridge for 15 to 30 minutes before injecting; cold solution makes flushing worse. Rotate injection sites between the abdomen, outer thigh, and upper arm. Co-supplementation is not optional either: at least 1000 mg/day calcium and 400 IU/day vitamin D throughout therapy. Without it, the risk of hypocalcemia goes up meaningfully. Store unopened vials at 2 to 8 degrees C. Once opened, use within 14 days.
Continuous daily use is standard for osteoporosis and Paget disease as prescribed. Cycling or intermittent dosing (e.g., alternating months) may be considered to mitigate antibody-mediated tolerance that can develop with prolonged therapy. Consult prescribing physician for individualized cycling decisions.
Calcitonin-salmon is a foreign (non-human) peptide. A subset of patients develop neutralizing IgG antibodies with chronic daily exposure, blunting receptor binding and therapeutic effect. Receptor downregulation (tachyphylaxis via CTR internalization) is an additional mechanism. Off-label cycling, typically continuous daily use for ~3 months followed by a 4-week drug holiday, may allow antibody titers to decline and receptor expression to recover. The FDA label specifies continuous daily dosing; cycling is NOT an FDA-endorsed protocol and should be disclosed as off-label.
Or use the universal Peptide Calculator for any peptide.
Expected: Modest lumbar spine BMD stabilization; possible vertebral fracture risk reduction (inferior to bisphosphonates). Analgesic benefit if concurrent bone pain present.
Monitor: Serum calcium at baseline and periodically. Alkaline phosphatase every 6 months. DEXA scan at baseline and every 1-2 years.
Dilute stock solution (200 IU/mL) to 10 IU/mL with normal saline. Inject 0.1 mL intracutaneously on the inner forearm. Wait 15 minutes. If a wheal or redness 15 mm or larger appears, calcitonin is contraindicated.
Remove the vial from the refrigerator (2 to 8 degrees C) and let it sit at room temperature for 15 to 30 minutes.
Using a U-100 insulin syringe (29 to 31 gauge, 1/2 inch needle), draw 0.5 mL from the vial. That's 50 units on the syringe, which equals 100 IU of calcitonin-salmon.
Clean the injection site (abdomen, outer thigh, or upper arm) with an alcohol swab. Pinch the skin and insert the needle at a 45 to 90 degree angle. Inject slowly over 20 to 30 seconds.
Administer in the evening, preferably after a meal, to reduce nausea.
Supplement daily with at least 1000 mg calcium and 400 IU vitamin D throughout therapy.
For hypercalcemia: calculate 4 IU per kilogram of body weight (a 70 kg patient gets 280 IU). Administer every 12 hours subcutaneous or intramuscular. If response is inadequate after one to two days, increase to 8 IU/kg every 12 hours.
Monitor serum calcium at baseline, monthly for the first three months, then every three to six months. Check alkaline phosphatase every three months for Paget disease.
200 IU/day intranasal (1 spray alternating nostrils daily): double the standard injectable dose
PROOF study (the key vertebral fracture endpoint RCT) used 200 IU/day nasal spray: this is the formulation with the fracture evidence. Injectable 100 IU/day lacks a direct fracture-endpoint RCT. Nasal brands (Fortical, Miacalcin NS) discontinued; generic nasal spray has limited US availability. Side effect profile differs: rhinitis, nasal irritation, epistaxis, sinusitis rather than flushing/nausea.
Same dose (100 IU); IM has marginally faster Tmax than SC, no clinically meaningful advantage
SC preferred for outpatient self-administration. IM used in clinical settings for patients unable to self-inject. Both routes explicitly listed in FDA label.
Redundant anti-resorptive mechanism. Concurrent use risks over-suppression of bone turnover with no additive fracture benefit. FDA label recommends against concurrent use.
Do not combineCalcitonin-induced hypocalcemia alters myocardial sensitivity to digitalis. Risk of digoxin toxicity or reduced efficacy. Monitor serum calcium and digoxin levels closely if concurrent use is unavoidable.
Calcitonin increases renal lithium clearance, reducing plasma lithium levels. May destabilize mood disorder management in lithium-dependent patients. Monitor lithium levels closely.
Additive risk of hypocalcemia. Calcitonin promotes renal calcium excretion; calcimimetics suppress PTH-driven calcium. Combined use requires close serum calcium monitoring.
Pricing updated 2026-04-09
The FDA label for calcitonin-salmon carries a malignancy signal: 4.1% cancer incidence in calcitonin-treated patients compared to 2.9% in placebo arms, pooled across 21 randomized controlled trials. A 2015 meta-analysis (PMC4715844) found this association was not statistically significant when basal cell carcinomas were excluded and concluded a causal link is "unlikely." No biological mechanism has been identified. The risk is formally unresolved; patients should be informed. Nausea is the most common complaint, affecting approximately 10% of patients on the injectable form. It tends to hit within 30 minutes of injection and usually improves over the first one to two weeks. Evening dosing after a meal helps. Some clinicians prescribe ondansetron 4 mg for the first few doses. Facial and hand flushing occurs in 2% to 5% of patients, typically within minutes of injection and resolving within an hour. This is a pharmacological response, not an allergic reaction in most cases. Letting the vial reach room temperature for 15 to 30 minutes before injecting and pushing the dose slowly over 20 to 30 seconds can reduce the intensity. Hypocalcemia is the direct pharmacological risk. Symptoms include muscle cramps, tetany, and paresthesias. The risk increases when calcium and vitamin D supplementation is inadequate. Serum calcium should be checked at baseline, monthly for the first three months, then every three to six months. Rare but documented: anaphylaxis. The FDA label requires an intradermal skin test before the first dose (0.1 mL of a 10 IU/mL dilution on the inner forearm, observed for 15 minutes). A positive reaction, meaning a wheal or erythema 15 mm or larger, is an absolute contraindication. Antibody formation develops in a subset of patients on chronic therapy. This can blunt the therapeutic response entirely. If biochemical markers of bone turnover plateau or start rising after an initial decline, tolerance is the likely explanation. A four-week drug holiday may restore response; if it doesn't, switching to a bisphosphonate or denosumab is appropriate. Other reported effects include diarrhea, abdominal discomfort, decreased appetite, urinary frequency, headache, dizziness, and tingling in the hands or feet. The nasal spray formulation trades the flushing and nausea for rhinitis, nasal irritation, epistaxis, and sinusitis. When to stop and see a doctor: persistent nausea that interferes with eating, signs of hypocalcemia (muscle spasms, numbness), any allergic symptoms (rash, swelling, difficulty breathing), or return of bone pain after a period of relief (possible tolerance).
Verify Calcitonin (Miacalcin) dosing and safety with a second opinion
FDA-approved pharmaceutical from licensed manufacturers (Mylan/Viatris generic). Supplied as ready-to-use 2 mL multi-dose vials (200 IU/mL). No reconstitution required. No compounding needed for standard therapeutic use. Well-characterized PK: bioavailability 66-71% SC/IM, t½ 58-64 min, Tmax ~23 min SC.
| Test | When | Target |
|---|---|---|
| Serum calcium | Baseline; monthly for first 3 months; every 3-6 months thereafter | 8.5-10.5 mg/dL |
| Serum alkaline phosphatase (ALP) | Baseline; every 3 months (Paget disease); every 6 months (osteoporosis) | 44-147 IU/L (lab-dependent) |
| 24-hour urinary hydroxyproline | Baseline and every 3-6 months (Paget disease) | Normal: <40 mg/day |
| DEXA scan (bone mineral density) | Baseline; every 1-2 years during therapy | Goal: stable or improving T-score |
| Intradermal skin test | Before first dose only (one-time) | — |
Calcitonin promotes renal calcium excretion; risk of hypocalcemia especially with inadequate calcium/vitamin D supplementation
Primary biomarker of bone turnover response in Paget disease. Declining ALP = therapeutic response; rising ALP after initial decline = suspected tolerance.
Marker of collagen breakdown (bone resorption rate). Normalization indicates Paget disease control.
Quantifies BMD changes at lumbar spine and femoral neck to assess osteoporosis treatment efficacy
Screens for calcitonin-salmon hypersensitivity; anaphylaxis is rare but documented. Required per FDA label.
Serum calcium begins to decline in hypercalcemic patients; analgesic effects may be noticed
Reduction in bone pain from Paget disease; decreased biochemical markers of bone turnover
Measurable decreases in serum alkaline phosphatase and urinary hydroxyproline in Paget disease
Stabilization or modest increase in bone mineral density at lumbar spine
Sustained fracture risk reduction with continued therapy; tolerance monitoring recommended
Hours 2 to 6. Serum calcium starts dropping, typically 1 to 2 mg/dL through increased renal excretion. Analgesic effects may begin. Nausea and facial flushing are most common during this window, usually resolving within an hour. Weeks 2 to 4. Bone pain from Paget disease or acute vertebral fractures starts easing. Biochemical markers of bone turnover (serum ALP, urinary hydroxyproline) begin their initial decline. The flushing and nausea that plagued the first few doses tend to fade by this point. WebMD reviewers (n=45) most frequently praised this time window for pain management. Months 1 to 3. Measurable drops in alkaline phosphatase and urinary hydroxyproline confirm the drug is working in Paget disease. BMD changes are too small to pick up this early. Osteoporosis patients comparing calcitonin to their prior bisphosphonate experience often feel underwhelmed. Months 6 to 12. Lumbar spine BMD stabilizes, with gains of 1% to 3% at best. Bisphosphonates produce 4% to 8% over the same period, and that difference shows. Antibody formation monitoring becomes relevant. Some patients report the drug seems less effective after six to nine months; this is consistent with receptor downregulation and antibody-mediated tolerance. Injection site reactions can accumulate without proper rotation. Years 1 to 3. The PROOF study supports sustained vertebral fracture risk reduction at five years with the 200 IU nasal spray. A 2025 Frontiers meta-analysis challenged this conclusion across calcitonin analog RCTs. Long-term injection adherence in the community is low; most patients switch or add agents if they can tolerate alternatives. FDA label malignancy monitoring applies to all patients on extended therapy.
Serum calcium declines 1-2 mg/dL via renal calcium excretion; analgesic effects may begin through endorphin-mediated and prostaglandin-inhibiting pathways
Limited community reports for hypercalcemia management. Users treating bone pain report "noticeable relief within a day or two."
Reduction in bone pain from Paget disease and acute vertebral fractures; initial decline in serum ALP and urinary hydroxyproline
Analgesic effect most consistently praised in WebMD reviews (n=45, 3.6/5); "managed my back pain for the first time in months" is a representative sentiment
Measurable ALP and urinary hydroxyproline decreases in Paget disease. BMD changes too small to detect meaningfully this early.
Paget patients report symptom improvement. Osteoporosis patients often compare calcitonin unfavorably to prior bisphosphonate experience.
Lumbar spine BMD stabilization (1-3% gain at best; bisphosphonates produce 4-8%). Antibody formation monitoring warranted.
Some patients report diminishing effect after 6-9 months, consistent with receptor escape/antibody formation.
PROOF study supports sustained vertebral fracture risk reduction at 5 years (200 IU nasal spray). 2025 Frontiers meta-analysis challenges this. FDA label malignancy monitoring required for long-term use.
Long-term injection adherence is low; most community users switch or add agents if tolerating alternatives. Few multi-year injection users documented.
Source: FDA Miacalcin label: 58-64 minutes IM/SC (PMID: 30725954)
Loading the interactive decay curve.
Calcitonin-salmon injection has held FDA approval since 1975 for postmenopausal osteoporosis (more than five years post-menopause), symptomatic Paget disease of bone, and hypercalcemia. It is classified as a prescription pharmaceutical, not a research chemical. Brand Miacalcin injection was commercially discontinued by Novartis. The FDA confirmed in February 2023 that this was a market decision, not a safety withdrawal. Generic calcitonin-salmon injection (Mylan/Viatris, 200 IU/mL) is currently available through licensed US pharmacies. Compounding is not necessary for standard therapeutic use. The EMA withdrew the nasal spray formulation from osteoporosis use across Europe in February 2013, citing the cancer risk signal. The injectable form remains available in the US for all three labeled indications. Calcitonin-salmon is not currently listed as a prohibited substance by WADA. Athletes should verify current status with their sport's governing body before use. This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy.
Peptide Schedule Research TeamReviewed Apr 20267 Citations
